Talaris Therapeutics Announces Initiation of Phase 3 Clinical Trial of FCR001 in Living Donor Kidney Transplant Recipients

Talaris Therapeutics, Inc. , a privately held biotechnology company developing transformative cell therapies that have the potential to eliminate the burden of chronic immunosuppression for organ transplant recipients, today announced the initiation of FREEDOM-1, the companys Phase 3 clinical trial of FCR001 in living donor kidney transplant (LDKT) recipients.